RESEARCH TRIANGLE PARK, N.C., June 3, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the completion of an underwritten public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. All of the shares were offered at a price to the public of $10.00 per share. The total gross proceeds from this offering to BioCryst, including the exercise of the option to purchase additional shares were $115 million, before deducting underwriting discounts and commissions and estimated offering expenses. BioCryst expects to use the net proceeds of this offering for general corporate purposes, including funding clinical development of BCX4161, the development of both second generation hereditary angioedema compounds, commercialization activities relating to peramivir and the advancement of other preclinical rare disease programs.
Help employers find you! Check out all the jobs and post your resume.
